<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB
(Mark One)

  /X/    QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE
         SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended              MARCH 31, 1998
                               ----------------------------------------

                                          OR

  / /    TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT


                       Commission file number 0-19567
                                              -------

                               CARDIAC SCIENCE, INC.
       -----------------------------------------------------------------
       (Exact name of Small Business Issuer as specified in its charter)


                 DELAWARE                                 33-0465681
        -------------------------------                ----------------
        (State or other jurisdiction of                (I.R.S. Employer
         incorporation or organization)                Identification No.)


    1176 MAIN STREET, SUITE C, IRVINE, CALIFORNIA                   92614
------------------------------------------------------------------------------
      (Address of principal executive offices)

Issuer's telephone number, including area code:           (949)  587-0357


Check whether the issuer (1) filed all reports required to be filed by 
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for 
such shorter period that the registrant was required to file such reports), 
and (2) has been subject to such filing requirements for the past 90 days. 
Yes  X   No 
    ---     ---

The number of shares of the Common Stock of the registrant outstanding as of 
May 14, 1998 was 5,134,560.


                                        1
<PAGE>



                              CARDIAC SCIENCE, INC.

                              INDEX TO FORM 10-QSB

                         PART I.  FINANCIAL INFORMATION

<TABLE>
<CAPTION>
                                                                              PAGE NO.
                                                                              --------
<S>         <C>                                                                  <C>
Item 1.     Financial Statements:

            Consolidated Condensed Balance Sheets March 31, 1998 (Unaudited)
              and December 31, 1997                                              3

            Consolidated Condensed Statements of Operations (Unaudited)
              Three months ended March 31, 1998 and 1997                         4

            Consolidated Condensed Statements of Cash Flows (Unaudited)
              Three months ended March 31, 1998 and 1997                         5

            Consolidated Condensed Notes to Financial Statements (Unaudited)     6

Item 2.     Management's Discussion and Analysis of
              Financial Condition and Results of Operation                       8

                        PART II. OTHER INFORMATION

Item 1.     Legal Proceedings                                                   12

Item 2.     Changes in Securities and Use of Proceeds                           12

Item 3.     Defaults Upon Senior Securities                                     12

Item 4.     Submission of Matters to a Vote of Security Holders                 12

Item 5.     Other Information                                                   12

Item 6.     Exhibits and Reports on Form 8-K                                    12

Signatures                                                                      13
</TABLE>

                                        2

<PAGE>



ITEM 1.  FINANCIAL STATEMENTS

                             CARDIAC SCIENCE, INC.


                     CONSOLIDATED CONDENSED BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                                       (Unaudited)      
                                                                                        March 31,     December 31,
                                                                                           1998           1997
                                                                                       -----------    ------------
                                                         ASSETS
<S>                                                                                    <C>            <C>
Current Assets:
  Cash and cash equivalents                                                            $   382,495    $   561,351
  Trade accounts receivable-net                                                            190,987        216,162
  Inventory                                                                                268,837        209,413
  Prepaid expenses                                                                         116,220         99,267
                                                                                       -----------    -----------
    Total current assets                                                                   958,539      1,086,193


Equipment, net                                                                              82,795         85,927
Intangible assets, net of amortization of $65,713 and $49,285, respectively                591,425        607,853
Other assets                                                                                 4,012          4,012
                                                                                       -----------    -----------
                                                                                       $ 1,636,771    $ 1,783,985
                                                                                       -----------    -----------
                                                                                       -----------    -----------

                                      LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current liabilities:
  Bank line of credit                                                                  $   200,000    $       ---
  Accounts payable and accrued expenses                                                  1,195,530      1,016,323
  Notes payable                                                                            256,305         70,233
                                                                                       -----------    -----------
    Total current liabilities                                                            1,651,835      1,086,556
                                                                                       -----------    -----------



Stockholders' Equity (Deficit):
  Preferred Stock - $.001 par value; 1,000,000 shares authorized, none
    issued or outstanding                                                                      ---            ---
  Common stock - $ 0.001 par value; 20,000,000 shares authorized, 4,984,560
    issued and outstanding at March 31, 1998 and 4,974,560 at
    December 31, 1997                                                                        4,985          4,975
  Additional paid-in capital                                                             7,471,110      7,472,107
  Accumulated deficit                                                                   (7,491,159)    (6,779,653)
                                                                                       -----------    -----------
    Total stockholders' equity (deficit)                                                   (15,064)       697,429
                                                                                       -----------    -----------
                                                                                       $ 1,636,771    $ 1,783,985
                                                                                       -----------    -----------
                                                                                       -----------    -----------
</TABLE>

    The accompanying notes are an integral part of the financial statements.


                                        3
<PAGE>

                              CARDIAC SCIENCE, INC.

                CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS                
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                           Three months           Three months
                                                              ended                  ended
                                                          March 31, 1998         March 31, 1997
                                                          --------------         --------------
<S>                                                         <C>                    <C>
Sales                                                       $   446,712            $       ---
Cost of Sales                                                   290,363                    ---
                                                            -----------            -----------
Gross Profit                                                    156,349                    ---

Operating Expenses:
  Research and development                                      419,738                 78,536
  Selling expenses                                              139,518                    ---
  General and administrative                                    302,170                 93,476
                                                            -----------            -----------

Loss from operations                                           (705,077)              (172,012)

Interest income (expense), net                                   (4,029)                 3,537
                                                            -----------            -----------

Loss before provision for income taxes                         (709,106)              (168,475)
Provision for income taxes                                        2,400                    ---
                                                            -----------            -----------

Net loss                                                    $  (711,506)           $  (168,475)
                                                            -----------            -----------
                                                            -----------            -----------

Basic and diluted loss per share                            $      (.14)           $      (.05)
                                                            -----------            -----------
                                                            -----------            -----------

Number of shares used in the computation of loss
  per share                                                   4,984,560              3,424,561
                                                            -----------            -----------
                                                            -----------            -----------
</TABLE>

    The accompanying notes are an integral part of the financial statements.

                                        4
<PAGE>



                             CARDIAC SCIENCE, INC.

                CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
                                 (Unaudited)

<TABLE>
<CAPTION>
                                                                              Three months          Three months
                                                                                  ended                 ended
                                                                             March 31, 1998        March 31, 1997
                                                                             --------------        --------------
<S>                                                                             <C>                  <C>
Cash flows from operating activities:

Net loss for the period                                                         $(711,506)           $(168,475)

Adjustments to reconcile net loss to net 
 Cash used in operating activities:
            Depreciation and amortization                                          22,428                3,019
            Expenses paid with common stock                                        20,000
            Changes in operating assets and liabilities:
             Trade receivables                                                     25,175                  ---
             Inventory                                                            (59,424)                 ---
             Prepaid expenses                                                     (16,953)              (1,235)
             Accounts payable and accrued expenses                                179,207              (13,690)
                                                                                ---------            ---------
Net cash used in operating activities                                            (541,073)            (180,381)
                                                                                ---------            ---------

Cash used by investing activities:
            Purchase of equipment                                                  (2,868)                 ---
                                                                                ---------            ---------
            Net cash used by investing activities                                  (2,868)                 ---
                                                                                ---------            ---------

Cash provided by financing activities:
            Payments of note payable to stockholder                               (13,928)
            Proceeds from line of credit                                          200,000                  ---
            Proceeds from note payable                                            200,000                  ---
            Costs of equity issuances                                             (20,987)
                                                                                ---------            ---------
            Net cash provided by financing activities                             365,085                  ---
                                                                                ---------            ---------

            Net increase (decrease) in cash and cash equivalents                 (178,856)            (180,381)
            Cash and cash equivalents at beginning of period                      561,351              413,311
                                                                                ---------            ---------

            Cash and cash equivalents at end of period                          $ 382,495            $ 232,930
                                                                                ---------            ---------
                                                                                ---------            ---------
</TABLE>

    The accompanying notes are an integral part of the financial statements


                                        5
<PAGE>



                             CARDIAC SCIENCE, INC.

       CONSOLIDATED CONDENSED NOTES TO FINANCIAL STATEMENTS (UNAUDITED)       
                                MARCH 31, 1998

1.       ORGANIZATION AND CAPITALIZATION OF THE COMPANY

         Cardiac Science, Inc. (the "Company") was incorporated on May 20, 
1991 to develop, manufacture and market a line of non-invasive (non-surgical) 
Automatic External Cardioverter Defibrillator ("AECD") devices (the 
"Products") to treat persons suffering from or at high risk of 
life-threatening arrhythmias. The Company's Products are designed to 
continuously monitor, quickly detect and then automatically, through 
transmission of electrical energy charges to the patient's heart, terminate 
the ventricular tachyarrhythmia (dangerously fast heart rate) and/or 
ventricular fibrillation (quivering of the heart following tachyarrhythmia, 
which usually results in death). Among the cardioverter/defibrillator devices 
under development by the Company are ambulatory (mobile) AECD devices similar 
in function to the Implantable Cardioverter Defibrillator ("ICD") devices 
that are either currently approved for sale by the U.S. Food and Drug 
Administration (the "FDA") or are undergoing clinical trials. However, the 
Company's planned AECD Products will not require surgery to implant the 
devices. Moreover, the Company's Products will not require the presence of a 
human operator to activate the device and deliver the defibrillator charge, 
as is the case with existing devices.

2.       BASIS OF PRESENTATION AND CONTINUED EXISTENCE

         Until the acquisition of Innovative Physician Services, Inc. d/b/a 
Diagnostic Monitoring ("Diagnostic Monitoring") on April 11, 1997 (see Note 
4), the Company was a development stage company engaged in the development of 
the Products for the treatment of arrhythmias that lead to cardiac arrest. 
Diagnostic Monitoring develops, manufactures and distributes cardiac devices 
and supplies, primarily PC-based Ambulatory ECG ("Holter") systems and Holter 
recorders on a worldwide basis.

         While the acquisition of Diagnostic Monitoring provides the Company 
with a revenue base, additional capital is needed to fulfill the Company's 
marketing, research and product development goals. From May 20, 1991 
(inception) through March 31, 1998, the Company incurred losses of 
approximately $7.5 million. Recovery of the Company's assets is dependent 
upon future events, the outcome of which is indeterminable. Additionally, 
successful completion of the Company's development program and its transition 
to attain profitable operations is dependent upon achieving a level of 
revenues adequate to support the Company's cost structure. The Company is 
currently attempting to identify other sources of financing. There can be no 
assurance that the Company will be successful in these areas.

3.       SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

         The consolidated financial statements include the accounts of the 
Company and of its wholly owned subsidiary, Diagnostic Monitoring. All 
inter-company accounts and transactions have been eliminated in consolidation.

         In the opinion of the Company's management, the accompanying 
consolidated condensed unaudited financial statements include all adjustments 
(which consist only of normal recurring adjustments) necessary for a fair 
presentation of its financial position at March 31, 1998 and results of 
operations and cash flows for the periods presented. Although the Company 
believes that the disclosures in these financial statements are adequate to 
make the information presented not misleading, certain information and 
disclosures normally


                                        6
<PAGE>

included in financial statements prepared in accordance with generally 
accepted accounting principles have been condensed or omitted and should be 
read in conjunction with the Company's audited financial statements included 
in the Company's 1997 Annual Report on Form 10-KSB. Results of operations for 
the three months ended March 31, 1998 are not necessarily indicative of 
results for the full year.

4.       ACQUISITION OF DIAGNOSTIC MONITORING

         On April 11, 1997, the Company acquired Diagnostic Monitoring for 
500 shares (5,714.285 pre-split) of the Company's Series A Convertible 
Preferred Stock (the "Preferred Stock") plus a non-interest bearing 
promissory note (the "Note") in the principal amount of $100,000, payable in 
eighteen (18) equal consecutive monthly installments commencing upon the 
earlier of April 9, 1999 or the completion of an equity financing by the 
Company of not less than $2,000,000 of gross proceeds. Each share of 
Preferred Stock was entitled to 1,000 votes per share; was convertible into 
1,000 shares of the Company's common stock, at any time, and from time to 
time, at the holder's option, without the payment of any additional 
consideration, and was automatically convertible into 1,000 shares of common 
stock (subject to adjustment for any reverse stock split, etc.) upon there 
being a sufficient number of authorized but unissued shares of common stock 
to allow such conversion. There were no dividend rights on the Preferred 
Stock. On September 8, 1997, the Company effectuated a one-for-11.42857413 
reverse stock split and the shares of Preferred Stock automatically converted 
into 500,000 shares of common stock.

         The total purchase price was $682,975, the fair market value of the 
Preferred Stock issued and the Note. The fair market value of the Preferred 
Stock issued was estimated based on the trading value of the common stock 
less a 30% discount to take into consideration the lack of the ability to 
trade and other features of the Preferred Stock. The fair market value of the 
Note represents the discounted value (at 11.25%) of the Note over 20 months.

         The transaction was accounted for under the purchase method of 
accounting and the purchase price was allocated to the fair market value of 
the assets acquired and liabilities assumed. The intangible assets resulting 
from the purchase price allocation is being amortized over 10 years using the 
straight-line method.

5.   PRIVATE PLACEMENT

         On April 26, 1998, the Company sold 150,000 shares of its common 
stock, at $2.00 per share, to a foreign investor in an offshore transaction 
pursuant to Regulation S promulgated under the Securities Act of 1933, as 
amended. The Company retained the $300,000 previously loaned ($200,000 on 
March 31, 1998 and an additional $100,000 on April 1, 1998) to the Company by 
such investor as full payment for the purchase price of the shares. In 
connection with the offering, the Corporation is obligated to pay a finder's 
fee equal to ten percent of the gross proceeds of the sale, payable in cash 
or common stock.

6.    STATEMENT OF FINANCIAL STANDARDS ADOPTED

         In June 1997, the FASB issued SFAS No. 131, "Disclosures About 
Segments of an Enterprise and Related Information". The Company has adopted 
the provisions of SFAS No. 131 with respect to it's wholly-owned subsidiary 
Diagnostic Monitoring, which was acquired April 11, 1997 (Note 4).

         All revenues reported for the three month period ending March 31, 
1998, $446,712, were derived from Diagnostic Monitoring. Net profit for this 
segment for the three month period ended March 31, 1998 was $47,848. Prior to 
the acquisition, all items of income and expense were derived from the 
operations of Cardiac Science, Inc. and therefore prior periods have not been 
restated to reflect segment data.


                                        7
<PAGE>

Item 2.     MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND 
            RESULTS OF OPERATION

GENERAL

         The following discussion should be read in conjunction with the 
consolidated financial statements of the Company and notes thereto set forth 
elsewhere in this Quarterly Report on Form 10-QSB.

         The Company is engaged in the development of non-invasive automatic 
defibrillator devices for the treatment of arrhythmias that lead to cardiac 
arrest. The Company commenced operations in May 1991. Until its acquisition 
of Diagnostic Monitoring in April 1997, its operations have consisted 
primarily of research and development activities and clinical FDA testing.

         Cardiac Science's Automatic External Cardioverter Defibrillator 
(AECD(R)) devices are designed to treat persons suffering from, or at high 
risk of, life-threatening arrhythmias (abnormal rhythms of the heart), such 
as ventricular tachycardia (dangerously rapid heart rate) and ventricular 
fibrillation (quivering of the heart), that lead to cardiac arrest. The AECD 
products will continuously monitor a patient's cardiac activity, detect 
abnormalities within seconds, and automatically, without human interaction, 
via disposable defibrillator pads attached to the patient's chest, transmit 
electrical shock (defibrillation) to convert the patient's heart to a normal 
rhythm. Reducing time to defibrillation is widely recognized as the most 
effective way to increase survival from cardiac arrest.

         There are three AECD devices under development by the Company. The 
Company's initial product, the Powerheart(R) defibrillator-monitor for 
in-hospital use, received 510(k) clearance from the United States Food and 
Drug Administration in October 1997 to allow it to begin marketing its 
Powerheart AECD in the United States. The additional AECD products under 
development include a light-weight, ambulatory vest model which can be worn 
continuously by at-risk cardiac patients and a fully automatic public access 
defibrillator which can be used by first responders and other non-technical 
individuals outside of the hospital environment.

         The Company's primary objective is to pioneer the commercialization 
of AECD devices that obviate the need for human intervention to successfully 
treat arrhythmias that lead to cardiac arrest. The Company believes the AECD 
Products are ideally suited for hospitalized and non-hospitalized patients 
temporarily at risk (periods ranging from days to months) of suffering 
cardiac arrest. Through its investment in clinical research, the Company 
believes it has established competitive functional and technological 
advantages in the development of AECD devices. The Company has been issued 
one patent, and has one additional patent under exclusive license relating to 
its AECD technology.

         In September 1997 the Company began work to complete development and 
begin production of the Powerheart(R) commercial model. Upon completion of 
the commercial model, of which there can be no assurance, the Company plans 
to sell the Powerheart(R) through a strategic U.S. distribution partner and 
overseas through existing its existing network of international distributors.

         Diagnostic Monitoring develops, manufactures and distributes cardiac 
devices and supplies, primarily PC-based Ambulatory ECG ("Holter") systems 
and Holter recorders, on a worldwide basis. Sales are made through qualified 
domestic and international distributors, pursuant to strategic distribution 
agreements, and managed by Diagnostic Monitoring employees on a 
country-by-country basis. Distribution is currently in place with market 
coverage in over 40 countries worldwide. In the United States, products are 
sold directly by


                                        8
<PAGE>

Diagnostic Monitoring to hospitals, physicians, and medical centers at prices 
that reflect market conditions. Diagnostic Monitoring's products are 
primarily made in the United States. Certain products and components are 
subcontracted and manufactured to Diagnostic Monitoring's specifications.

         RESULTS OF OPERATIONS

         For the three months and year to date ended March 31, 1998, the 
Company had revenues of $446,712 and a net loss of $711,506 compared to no 
revenues and a net loss of $168,475 for the three months and year to date 
period ended March 31, 1997.

         Revenues generated for the three months and year to date ended March 
31, 1998 are attributable to the sale of products by its subsidiary, 
Diagnostic Monitoring. Gross profit on sales for the period ending March 31, 
1998 was 35%. Sales of Diagnostic Monitoring's Windows 95(R) compatible 
Holter software and systems, Holter Recorder products, and related Holter 
supplies represented 78% of the Company's total revenue. Sales of Spirometers 
accounted for 3.5% and PC-based Electrocardiographs accounted for 5.2%. 
Export sales of Diagnostic Monitoring's products to international countries 
represented 85% of the Company's revenue, with the balance of sales coming 
from within the United States.

         The increased loss for the quarter and year to date period ended 
March 31, 1998 is primarily attributable to increased operating costs offset 
by an increase in gross margins.

         Research and development expenses increased to $419,738 for the 
three months and year to date period ended March 31, 1998, as compared to 
$78,536 for the three month and year to date period ended March 31, 1997. 
This increase was due to pre-production costs associated with the 
commercialization of the Company's initial AECD(R) product, the Powerheart(R).

         Selling expenses for the three months and year to date period ended 
March 31, 1998 were $139,518, compared to no expenses in the three months and 
year to date period ended March 31, 1997 reflecting the marketing efforts for 
the Holter Product line and pre-marketing expense for the Powerheart(R).

         General and administrative expenses increased to $302,170 for the 
three month and year to date period ended March 31, 1998, from $93,476 for 
the same period in 1997. The increase was a result of expenditures incurred 
to support both the Holter Product line (acquired in 1997) and infrastructure 
necessary to commercialize the Powerheart and begin initial preparations for 
market release. Expenses, which increased in 1998 as compared to 1997, 
included amortization of intangible assets, personnel costs and related 
fringes, insurance premiums for both product liability and directors and 
officers insurance, and professional fees.

         Interest expense, net, increased to $4,029 for the three month and 
year to date period ended March 31, 1998 as compared to interest income, net 
of $3,537 for the same period in the prior year, due to the debt incurred in 
the acquisition of Diagnostic Monitoring and borrowings on the bank line of 
credit in 1998.

LIQUIDITY AND CAPITAL RESOURCES

         At March 31, 1998, the Company had cash and cash equivalents of 
$382,495 and a working capital deficit of $693,296 as compared to cash and 
cash equivalents of $561,351 and negative working capital of $363 at December 
31, 1997. From inception, the Company's sources of funding for operations 
were derived from equity placements aggregating approximately $7,500,000. The 
Company has incurred losses of approximately $7,500,000 since inception and 
expects to incur substantial additional operating losses as a result


                                        9
<PAGE>

of expenditures related to the marketing and sales support functions, 
research and product development activities, completion and initiation of 
clinical trials for current and future products and costs associated with the 
development of a commercial model and pre-production costs for the 
Powerheart(R) product. The timing and amounts of these expenditures will 
depend upon many factors, some of which are beyond the Company's control, 
such as the results of clinical trials, the requirements for and time 
required to obtain approval of 510(k) applications or other regulatory 
approvals, the progress of the Company's research and development programs, 
and market acceptance of the Company's products

         The Company anticipates that its current cash balance will be 
sufficient to meet the Company's cash requirements for at least the next 4 
months. Given the current sales volume and applications of cash, the Company 
expects that further capital additions will be necessary to sustain growth 
until the Company becomes cash positive. In this respect, the Company is 
considering a number of alternatives, including additional equity financings 
and corporate partnerships. There can be no assurance that any such 
transactions will be available at terms acceptable to the Company or that any 
financing transaction will not be dilutive to current stockholders or that 
the Company will have sufficient working capital to fund future operations.

FORWARD LOOKING STATEMENTS

         The Company desires to take advantage of certain provisions of the 
Private Securities Litigation Reform Act of 1995 that provide a "safe harbor" 
for forward looking statements made by or on behalf of the Company. Except 
for the historical information contained herein, the matters discussed herein 
are forward looking statements. The forward looking statements contained in 
this Quarterly Report on Form 10-QSB are subject to various risks, 
uncertainties and other factors that could cause actual results to differ 
materially from the results anticipated in such forward looking statements. 
Included among the important risks, uncertainties and other factors are those 
hereinafter discussed, the accuracy of which is necessarily subject to risks 
and uncertainties.

         Few of the forward looking statements in this Quarterly Report on 
Form 10-QSB deal with matters that are within the unilateral control of the 
Company. There is substantial regulation of the manufacture and sale of 
medical products, including many of the Company's products, by governmental 
agencies in the United States and foreign countries. These government 
agencies often have considerable discretion in determining whether and when 
to approve the marketing of the Company's products that have not yet received 
such approval.

         The availability of equity and debt financing to the Company is 
affected by, among other things, domestic and world economic conditions and 
the competition for funds. Rising interest rates might affect the feasibility 
of debt financing that is offered. Potential investors and lenders will be 
influenced by their evaluations of the Company and its products and 
comparisons with alternative investment opportunities.

         Many of the Company's competitors have greater financial resources 
and technical capabilities than the Company, which may enable such 
competitors to design and produce superior products or to market their 
products in a manner that achieves commercial success even in the face of 
technical superiority on the part of the Company's products.


                                        10
<PAGE>

         The Company's patents may not offer effective protection against 
competitors. Competitors may be able to design around the Company's patents 
or employ technologies not covered by such patents. In addition, the 
Company's patents may be challenged, and even if such patents are upheld, the 
diversion of financial and human resources associated with patent litigation 
could adversely affect the Company. The Company may be found to be violating 
the patents of others and forced to obtain a license under such patents or 
modify the design of its products.

         Rapid technological developments are expected to continue in the 
industries in which the Company competes. The Company may not be able to 
develop, manufacture and market products which meet changing user 
requirements or which successfully anticipate or respond to technological 
changes in a cost-effective and timely manner.


                                        11
<PAGE>

                             CARDIAC SCIENCE, INC.

                          PART II.  OTHER INFORMATION

Item 1.         LEGAL PROCEEDINGS

                None.

Item 2.         CHANGES IN SECURITIES AND USE OF PROCEEDS

                None.

Item 3.         DEFAULTS UPON SENIOR SECURITIES

                None.

Item 4.         SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

                None.

Item 5.         OTHER INFORMATION

                None.

Item 6.         EXHIBITS AND REPORTS ON FORM 8-K

                a)    None.
                b)    None.


                                        12
<PAGE>

                                   SIGNATURES


In accordance with the requirements of the  Exchange Act, the registrant 
caused this report to be signed on its behalf by the undersigned, hereunto 
duly authorized.

                                       CARDIAC SCIENCE, INC.




Date: MAY 14, 1998                     /s/ Brett L. Scott
--------------                         -------------------
                                       Brett L. Scott
                                       Chief Financial Officer




                                       13